OIS@AAO 2017 Videos

This company has developed a cell-based therapy (jCell) to preserve and restore vision in people with retinitis pigmentosa (RP), although the therapy is potentially applicable…

Nightstar’s mission is to maintain and restore vision in blinding inherited retinal diseases. To that end, the company has seven retinal programs under license. Its…

Devoted to developing genetic therapies through the use of vector technologies and dosing for patients with inherited retinal diseases, AGTC has partnered with Biogen and…

The AcuFocus platform differs from other solutions in that others rearrange the blur commonly found with presbyopia and other refractive errors, while the AcuFocus platform…

The current standard of care for glaucoma involves reducing intraocular pressure, whether through medication use or surgery, or some combination of the two. But with…

Nancy Lurker, president and CEO, reports data from two Phase III trials for Durasert’s use in treating uveitis. The company plans to file an NDA…

OIS Co-chair and Clarus Funds Managing Director Emmett T. Cunningham Jr., MD, PhD, MPH, delivered a complete overview of the new ophthalmology treatments. In this…